---
title: "Krystal Biotech, Inc. (KRYS.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/KRYS.US.md"
symbol: "KRYS.US"
name: "Krystal Biotech, Inc."
industry: "Biotechnology"
datetime: "2026-05-21T17:32:58.672Z"
locales:
  - [en](https://longbridge.com/en/quote/KRYS.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/KRYS.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/KRYS.US.md)
---

# Krystal Biotech, Inc. (KRYS.US)

## Company Overview

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.krystalbio.com](https://www.krystalbio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:16.000Z

**Overall: B (0.25)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 21 / 385 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 25.15% |  |
| Net Profit YoY | 81.53% |  |
| P/B Ratio | 6.97 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 8904360299.80 |  |
| Revenue | 417304000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 19.90% | A |
| Profit Margin | 53.92% | A |
| Gross Margin | 94.57% | A |
| Revenue YoY | 25.15% | A |
| Net Profit YoY | 81.53% | A |
| Total Assets YoY | 30.02% | A |
| Net Assets YoY | 29.66% | A |
| Cash Flow Margin | 111.22% | C |
| OCF YoY | 25.15% | A |
| Turnover | 0.34 | D |
| Gearing Ratio | 8.61% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Krystal Biotech, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "25.15%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "81.53%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "6.97",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "8904360299.80",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "417304000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "19.90%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "53.92%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "94.57%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "25.15%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "81.53%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "30.02%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "29.66%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "111.22%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "25.15%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.34",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "8.61%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 39.57 | 49/385 | 38.43 | 35.67 | 30.31 |
| PB | 6.97 | 363/385 | 6.52 | 5.40 | 4.16 |
| PS (TTM) | 21.34 | 194/385 | 20.31 | 16.02 | 12.11 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **11**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 10 | 91% |
| Hold | 1 | 9% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 303.69 |
| Highest Target | 380.00 |
| Lowest Target | 241.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/KRYS.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/KRYS.US/norm.md)
- [Related News](https://longbridge.com/en/quote/KRYS.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/KRYS.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**